Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brequinar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 19/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brequinar SCHEMBL29355220 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL29688590 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23832490 | 1.00 | DHODH (1.00) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL11906320 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23113785 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL21378179 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL23828306 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL4266 | 0.99 | DHODH (0.98) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL27742234 | 0.97 | DHODH (0.94) | DHODHDHFRALKBH5PDE10A | |
| Brequinar SCHEMBL4177875 | 0.96 | DHODH (0.92) | DHODHDHFRALKBH5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8740 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130991-A1 | HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF | PRIMATOPE THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739299-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260103532-A1 | PHARMACEUTICAL COMPOSITIONS OF HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF | KINIKSA PHARMACEUTICALS GMBH (CH) | 2026-04-16 | — | — | US | claimed |
| US-12594271-B2 | Combination therapy for cancer | HEALTH RESEARCH, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4704867-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | Sana Biotechnology, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048086-A1 | METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS | SANA BIOTECHNOLOGY INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4697909-A1 | ENCAPSULATED PEROVSKITE SOLAR CELL MODULE AND PREPARATION METHOD | Xi'an TJ-Solar New Energy Co., Ltd (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4626439-A2 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA | The Regents of the University of Colorado, a body corporate (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3858361-B1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORP (JP) | 2025-10-08 | — | — | EP | claimed |
| US-20250302817-A1 | METHODS FOR TREATING PTEN-MUTANT TUMORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-02 | — | — | US | claimed |
| US-5032597-A | Antitumor | DU PONT MERCK PHARMACEUTICAL (US) | 1991-07-16 | — | — | US | claimed |
| EP-0133244-B1 | PHENYLQUINOLINECARBOXYLIC ACIDS AND DERIVATIVES AS ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-05 | — | — | EP | claimed |
| US-4968701-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-06 | — | — | US | claimed |
| EP-0362578-A1 | Treatment of cancer in mammals by concurrent administration of 4-quinoline carboxylic acid derivatives and interleukin-2 | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-11 | — | — | EP | claimed |
| US-4889862-A | BILE SALT STABILIZER FOR ANTITUMOR INJECTABLE SOLUTION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-26 | — | — | US | claimed |
| EP-0339484-A1 | 4-Quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0339485-A1 | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-11-02 | — | — | EP | claimed |
| US-4861783-A | TOPICAL APPLICATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-29 | — | — | US | claimed |
| US-4680299-A | ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-14 | — | — | US | claimed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | claimed |